Circulating the HLA-DR+ T Cell Ratio Is a Prognostic Factor for Recurrence of Patients with Hepatocellular Carcinoma after Curative Surgery

Table 6

Univariate Cox regression analyses of risk factors associated with progression-free survival and overall survival after curative surgery for AFP-negative (<20 ng/ml) hepatocellular carcinoma.

Variables	HR comparison	Progression-free survival		Overall survival
		UV HR (95% CI)	UV value	UV HR (95% CI)	UV value
Gender	Male vs. female	3.477 (0.828–14.578)	0.088	1.856 (0.237–14.538)	0.556
Age	≥60 vs. <60 years	0.758 (0.377–1.524)	0.436	0.451 (0.119–1.707)	0.241
Liver cirrhosis	Yes vs. no	1.627 (0.786–3.367)	0.190	3.203 (0.689–14.893)	0.138
AST/ALT	≥1 vs. <1	0.958 (0.443–2.072)	0.914	1.635 (0.471–5.678)	0.439
GGT level	≥45 U/L vs. <45 U/L	1.910 (0.938–3.887)	0.074	3.591 (1.083–11.907)	0.037
CD3+T cell ratio	≥77% vs. <77%	0.802 (0.330–1.952)	0.627	1.737 (0.448–6.742)	0.425
CD4+ T cell ratio	≥41.6% vs. <41.6%	1.024 (0.483–2.171)	0.950	1.073 (0.280–4.117)	0.918
CD8+ T cell ratio	≥29.6% vs. <29.6%	0.672 (0.310–1.458)	0.314	1.087 (0.317–3.736)	0.894
HLADR+ T cell ratio	≥5.8% vs. <5.8%	0.548 (0.275–1.093)	0.088	1.351 (0.394–4.629)	0.632
B cell ratio	≥18.2% vs. <18.2%	1.910 (0.787–4.633)	0.152	1.353 (0.291–6.278)	0.700
NK cell ratio	≥25.6% vs. <25.6%	0.650 (0.227–1.864)	0.423	0.487 (0.062–3.280)	0.493
Edmondson grade	III-IV vs. I-II	1.525 (0.738–3.149)	0.254	3.500 (1.067–11.481)	0.039
Largest tumor size	≥5 cm vs. <5 cm	1.911 (0.901–4.052)	0.091	3.779 (1.128–12.665)	0.031
Microvascular invasion	Yes vs. no	1.144 (0.544–2.406)	0.723	1.926 (0.587–6.324)	0.280
Capsular invasion	Yes vs. no	1.724 (0.863–3.445)	0.123	2.136 (0.645–7.706)	0.214

AFP: alpha-fetoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma glutamyl transferase.